Neboglamine hydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Neboglamine (CR-2249, XY-2401) hydrochloride 是一种具有口服活性的 NMDA 受体甘氨酸位点的正向调节剂，可用于精神分裂症研究。

Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research.

——

Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats.Animal Model:Male Wistar ratsDosage:20 mg/kg Administration: Subcutaneous injectionResult:Increased neuronal activity in brain regions, prefrontal cortex (PFCX) from 38.5 to 121.3, nucleus accumbens (NAc) from 14.5 to 69.1 and lateral septal nucleus (LSN) from 16.2 to 73.1 but no effect on dorsolateral striatum (DL-STR) compared to the control group.Significantly inhibited phencyclidine-induced hypermobility.Animal Model:Male Wistar rats Dosage:0.3 mg/kg, 3 mg/kg, 30 mg/kg Administration: Oral administration Result: Reduced frequency of PCP-induced hypermobility and stereotyped behaviour in a dose-dependent manner and the dose inhibited stereotyped behaviour (0.3 mg/kg) was lower than the dose inhibited motor activity (3 mg/kg).

——

Membrane Transporter/Ion Channel

NMDAR

NMDAR

——

——

2759182-59-5

292.8

C13H25ClN2O3

>98% (HPLC)

——

N(C([C@H](CCC(O)=O)N)=O)C1CCC(C)(C)CC1.Cl

——

(-20℃)

With Ice Pack

≥ 2 years